<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Victoria Hendrick, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Louise Wilkins-Haug, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H23370694">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications are commonly used to treat pregnant patients, including those with manic and hypomanic episodes [
         <a href="#rid1">
          1
         </a>
         ]. At least one prescription drug is taken by more than 80 percent of pregnant patients across the world [
         <a href="#rid2">
          2
         </a>
         ] and psychotropic drugs are taken by at least 10 percent [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         This topic discusses pharmacotherapy for pregnant patients with mania or hypomania. Treatment of bipolar major depression during pregnancy, prenatal maintenance pharmacotherapy for bipolar disorder, the teratogenic and postnatal risks of medications used for bipolar disorder, and the general treatment of mania and hypomania are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/82788.html" rel="external">
          "Bipolar disorder in pregnant women: Treatment of major depression"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1029357">
         <span class="h1">
          DEFINITION OF BIPOLAR DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2172441772">
         <span class="h1">
          SCREENING AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         An overview of screening for bipolar disorder in pregnant women and making the diagnosis is presented in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef122826" href="/z/d/graphic/122826.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid5">
          5,6
         </a>
         ]. Screening is usually performed in early pregnancy [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         We suggest initially screening for depression using the self-report, 10-item Edinburgh Postnatal Depression Scale  (
         <a class="graphic graphic_figure graphicRef67741" href="/z/d/graphic/67741.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef81407" href="/z/d/graphic/81407.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ]. A reasonable alternative is the self-report, nine-item Patient Health Questionnaire  (
         <a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid9">
          9-13
         </a>
         ]. Screening pregnant women for depression, with services in place to ensure follow-up for diagnosis and treatment, is consistent with the practice guidelines issued by the United States Preventive Services Task Force [
         <a href="#rid9">
          9,14
         </a>
         ] and the Canadian Network for Mood and Anxiety Treatments [
         <a href="#rid15">
          15
         </a>
         ] and is strongly recommended by the American Psychiatric Association [
         <a href="#rid16">
          16
         </a>
         ]. Patients who screen positive for depression are then screened for bipolar disorder, using the self-report, 15-item Mood Disorder Questionnaire  (
         <a class="graphic graphic_table graphicRef53409" href="/z/d/graphic/53409.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid17">
          17-19
         </a>
         ]. In using the Mood Disorder Questionnaire, we suggest ignoring the question about concurrent symptoms in section two and the question about psychosocial functioning in section three. A reasonable alternative to the Mood Disorder Questionnaire is the clinician administered, 12-item Composite International Diagnostic Interview  (
         <a class="graphic graphic_table graphicRef122568" href="/z/d/graphic/122568.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         Evidence supporting this approach includes studies that suggest bipolar disorder is present in up to 20 percent of pregnant or postpartum women who screen positive for depression in primary care or obstetric clinics [
         <a href="#rid22">
          22
         </a>
         ]. In addition, a study of women receiving prenatal care in an obstetric clinic, who were routinely administered the Edinburgh Postnatal Depression Scale and Mood Disorder Questionnaire, found that the likelihood of a positive screen for bipolar disorder was higher in women who initially screened positive for depression, than women who screened negative for depression (odds ratio 12) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Although questions have been raised as to whether the Mood Disorder Questionnaire performs well enough to recommend its use [
         <a href="#rid24">
          24
         </a>
         ], multiple studies in psychiatric settings have found that disregarding the question about psychosocial functioning in section three improved the instrument’s psychometric properties, such that sensitivity was good to excellent and specificity was fair to excellent [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         In addition, studies of perinatal women have also found that the Mood Disorder Questionnaire can be a useful screening tool [
         <a href="#rid25">
          25
         </a>
         ]. As an example, a study enrolled pregnant (n = 95) or postpartum (n = 55) patients who were referred to a women’s mental health program and administered the Mood Disorder Questionnaire and conducted diagnostic interviews [
         <a href="#rid26">
          26
         </a>
         ]. After disregarding the question about concurrent symptoms in section two and the question about psychosocial functioning in section three, both the sensitivity (89 percent) and specificity (84 percent) were excellent.
        </p>
        <p>
         Patients who screen positive for bipolar disorder require an interview to establish the diagnosis. Bipolar I disorder is diagnosed in patients with a current or past history of at least one manic episode  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]. Bipolar II disorder is diagnosed in patients with a history of at least one episode of hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), at least one episode of major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ), and no history of mania. Additional information about diagnosing bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Patients who screen positive for depression but not for bipolar disorder require an interview to establish the diagnosis of unipolar depression. Unipolar major depression (major depressive disorder) is characterized by a history of one or more major depressive episodes  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 7
         </a>
         ) and no history of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ) or hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]. Additional information about diagnosing unipolar major depression and other unipolar depressive syndromes is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H87627918">
         <span class="h1">
          INDICATIONS FOR PHARMACOTHERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacotherapy is indicated for pregnant patients with manic and hypomanic episodes that are characterized by [
         <a href="#rid28">
          28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suicidal or homicidal ideation or behavior
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggressive behavior
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychotic features (delusions or hallucinations)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor judgement that places the patient or others at imminent risk of being harmed
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to severe impairment of social or occupational functioning
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement in pleasurable activities that have a high potential for painful consequences (eg, unrestrained buying sprees or sexual indiscretions)
        </p>
        <p>
        </p>
        <p>
         Medications may not be indicated for relatively mild episodes of hypomania. However, it is not clear which untreated hypomanic episodes will progress to mania that requires pharmacotherapy.
        </p>
        <p class="headingAnchor" id="H86321418">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3324848">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar mood episodes during pregnancy are usually treated by perinatal or general psychiatrists in collaboration with obstetricians and primary care clinicians [
         <a href="#rid29">
          29-33
         </a>
         ].
        </p>
        <p>
         For manic and hypomanic pregnant patients, treatment is based upon randomized trials that excluded pregnant patients [
         <a href="#rid34">
          34
         </a>
         ], as well as observational studies, birth registries, and clinical experience [
         <a href="#rid35">
          35
         </a>
         ]. Preferred drugs include medications that were effective and well tolerated prior to pregnancy and have a relatively favorable reproductive safety profile [
         <a href="#rid36">
          36
         </a>
         ]. For patients who are taking medications at the time of conception and are clinically stable, it is generally preferable to continue the same regimen rather than switch medications. Switching exposes the fetus to additional medications and may increase the risk of recurrent mood episodes in the mother. However, changing medications is reasonable for women who are taking
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         when they become pregnant. (See
         <a class="local">
          'Drugs that are avoided'
         </a>
         below.)
        </p>
        <p>
         To reduce the risk of teratogenic and postnatal effects in the offspring of pregnant bipolar patients who are treated with pharmacotherapy, clinicians should attempt to use [
         <a href="#rid29">
          29,36,37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs with fewer known teratogenic and postnatal effects
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monotherapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The minimal effective dose
        </p>
        <p>
        </p>
        <p>
         The risks of teratogenic and postnatal effects from medications commonly used to treat bipolar disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         .)
        </p>
        <p>
         Although monotherapy is desirable, medication combinations may be necessary during pregnancy and appear to be common [
         <a href="#rid32">
          32,38-40
         </a>
         ]. As an example, a prospective study found that among 54 pregnant patients with bipolar disorder who were treated with psychotropic medications (eg, antipsychotics,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and/or antidepressants), polypharmacy occurred in 65 percent [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         We avoid using subtherapeutic doses because they may precipitate maternal illness and do not eliminate fetal exposure [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         For pregnant patients with bipolar mood episodes that occur during maintenance pharmacotherapy, we favor increasing the dose within the therapeutic dose range rather than starting a second medication [
         <a href="#rid29">
          29,42,43
         </a>
         ]. This includes ensuring serum concentrations are in the therapeutic range for medications such as
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , as well as increasing the dose to achieve a higher serum level within the therapeutic range, provided that side effects do not intervene. However, as described above, many patients require medication combinations.
        </p>
        <p class="headingAnchor" id="H2001176">
         <span class="h2">
          Setting
         </span>
         <span class="headingEndMark">
          —
         </span>
         The setting for prenatal treatment of bipolar mood episodes depends upon the type and severity of symptoms, level of psychosocial functioning, and available support [
         <a href="#rid42">
          42,44,45
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inpatient hospitalization is often required for safety and stabilization of patients with severe symptoms (eg, suicidal ideation with a specific plan or intent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial hospital (day) treatment may be feasible for managing moderate symptoms (eg, suicidality that does not pose an imminent risk, such as fleeting thoughts of killing oneself with vague or nonexistent plans and no intent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Outpatient treatment may be suitable for patients with less acute symptoms (eg, thoughts that family members would be better off if the patient was dead, with no plan or intent to commit suicide)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H32030536">
         <span class="h2">
          Monitoring patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The psychiatric status of pregnant bipolar patients should be regularly monitored, with particular attention to suicidal ideation and psychosis [
         <a href="#rid46">
          46,47
         </a>
         ]. Patients taking medications are also assessed for therapeutic and adverse effects. In addition, serum concentrations of medications with established therapeutic levels (eg,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ) should be checked. Monitoring pregnant patients who take lithium is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Refractory patients'
         </a>
         .)
        </p>
        <p>
         The frequency of assessing pregnant bipolar patients generally ranges from daily to monthly, depending upon the type and severity of symptoms. Hospitalized patients are monitored daily, and patients with active suicidal ideation, a specific plan, and intent to kill themselves typically require constant observation. Outpatients who have not achieved substantial improvement in the number, intensity, and frequency of symptoms are generally seen weekly; patients who have improved substantially may be seen every two to four weeks until they remit.
        </p>
        <p class="headingAnchor" id="H16652974">
         <span class="h2">
          Duration of an individual drug trial
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest treating pregnant patients with mania and hypomania for three weeks before determining whether a specific drug is beneficial, based upon the duration of most randomized trials (which excluded pregnant patients) [
         <a href="#rid34">
          34
         </a>
         ]. Response is defined as stabilizing the patient’s safety and substantial improvement in the number, intensity, and frequency of symptoms.
        </p>
        <p class="headingAnchor" id="H1302549">
         <span class="h1">
          CHOOSING SPECIFIC MEDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite clinical differences between mania and hypomania (eg, hypomania is less severe than mania), for the purpose of treatment these mood elevated syndromes are considered to be similar and thus treated with the same medications [
         <a href="#rid42">
          42,44,45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13589500">
         <span class="h2">
          First-line medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         For manic and hypomanic pregnant patients, we suggest first-generation antipsychotics, which have been widely used during pregnancy [
         <a href="#rid29">
          29,36,48
         </a>
         ]. Using antipsychotics as first-line treatment is consistent with practice guidelines [
         <a href="#rid15">
          15,49
         </a>
         ], including the British Association for Psychopharmacology [
         <a href="#rid46">
          46
         </a>
         ] and the United Kingdom National Institute for Health and Care Excellence [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Among antipsychotics, we prefer
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , based upon its demonstrated efficacy in randomized trials (which excluded pregnant patients) [
         <a href="#rid34">
          34
         </a>
         ] and other studies that suggest haloperidol is not associated with an increased risk of congenital anomalies [
         <a href="#rid29">
          29,36,50
         </a>
         ]. In addition, using haloperidol is consistent with practice guidelines from the British Association for Psychopharmacology [
         <a href="#rid46">
          46
         </a>
         ], and haloperidol is preferred by many experts [
         <a href="#rid1">
          1,39,51
         </a>
         ]. Other first-generation antipsychotics that are reasonable alternatives to haloperidol include
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         [
         <a href="#rid52">
          52
         </a>
         ]. Clinicians can expect that response to a first-generation antipsychotic will occur in approximately 50 percent of patients, based upon trials in nonpregnant patients [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         for treating mood elevated syndromes appears to be comparable to
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , and superior to
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]. In addition, there is more experience using haloperidol during pregnancy compared with second-generation antipsychotics, and the reproductive safety profile of haloperidol is generally regarded as superior to lithium. The efficacy of haloperidol, risperidone, olanzapine, quetiapine, and lithium (in randomized trials that excluded pregnant patients) is discussed separately, as is the reproductive safety profile of these drugs, and the dose, side effect profile  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 8
         </a>
         ), and pharmacology of haloperidol. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         .)
        </p>
        <p>
         For pregnant bipolar patients who cannot tolerate the usual minimal therapeutic dose of
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         (5 to 10 mg per day) because of extrapyramidal symptoms (EPS), we suggest cautiously reducing the dose (eg, by 1 to 2 mg per day), while closely monitoring the patient for exacerbation of mood elevated symptoms. If decreasing the dose is unfeasible or inadequate, we suggest tapering and discontinuing haloperidol over one to two weeks and at the same time starting and titrating up a low-potency agent (eg,
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ). Haloperidol is tapered by the same amount for each dose decrease. As an example, haloperidol 8 mg per day is decreased by 2 mg per day every one to three days. The dose and side effects of chlorpromazine are discussed separately.
        </p>
        <p>
         For pregnant patients receiving
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         who develop Parkinsonism or dystonia, a reasonable alternative to switching drugs is to add
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         . Reviews suggest that the risk of teratogenicity with antihistamines such as diphenhydramine appears to be low [
         <a href="#rid54">
          54
         </a>
         ] and that fetal organ malformation appears to be less likely with diphenhydramine than
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         [
         <a href="#rid55">
          55,56
         </a>
         ]. Additional information about the treatment of EPS and the teratogenic risks of antiparkinsonian drugs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Antiparkinsonian drugs used for treating extrapyramidal symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Extrapyramidal symptoms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1303216">
         <span class="h2">
          Resistant patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our clinical experience, pregnant patients with manic and hypomanic episodes often do not respond to or tolerate
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         . (Response is defined as stabilizing the patient’s safety and substantial improvement in the number, intensity, and frequency of symptoms.) For these resistant patients, we suggest in order of preference
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , based upon their efficacy and side effects in randomized trials (that excluded pregnant patients) [
         <a href="#rid34">
          34
         </a>
         ], as well as study findings that suggest these drugs are not associated with an increased risk of major malformations [
         <a href="#rid40">
          40,57,58
         </a>
         ]. Using second-generation antipsychotics during pregnancy is consistent with the practice of many perinatal psychiatrists [
         <a href="#rid39">
          39
         </a>
         ]. Up to 50 to 60 percent of patients may respond, based upon trials in nonpregnant patients [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         appears to be superior to
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ; quetiapine appears to be better tolerated than olanzapine; and although the efficacy of quetiapine and lithium appear comparable, quetiapine may be better tolerated [
         <a href="#rid34">
          34
         </a>
         ]. In addition, study findings suggest that second-generation antipsychotics are not associated with an increased risk of major malformations [
         <a href="#rid39">
          39,40,57,58
         </a>
         ], whereas lithium is generally regarded as teratogenic [
         <a href="#rid59">
          59-61
         </a>
         ]. The preference for treating pregnant bipolar patients with risperidone, quetiapine, or olanzapine rather than lithium is consistent with practice guidelines from the United Kingdom National Institute for Health and Clinical Excellence [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         However, second-generation antipsychotics, particularly
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , may cause metabolic complications (eg, hyperglycemia and obesity) that are associated with risks to the mother and fetus [
         <a href="#rid62">
          62,63
         </a>
         ]. These risks are discussed separately, as is monitoring of metabolic parameters in pregnant patients taking second-generation antipsychotics. (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Metabolic complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14775.html" rel="external">
          "Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">
          "Modifiable risk factors for cardiovascular disease in patients with severe mental illness"
         </a>
         .)
        </p>
        <p>
         To switch drugs,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         is tapered and discontinued over one to two weeks while at the same time
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         is started and titrated up. We generally taper haloperidol by the same amount for each dose decrease. As an example, haloperidol 8 mg per day is decreased by 2 mg per day, every one to three days. For resistant pregnant bipolar patients who do not respond to or tolerate treatment with one second-line medication, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another second-line medication is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example, risperidone 6 mg per day is decreased by 1 to 2 mg per day, every one to three days.
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         for treating mood elevated syndromes (in randomized trials that excluded pregnant patients) is discussed separately, as are the doses, side effects  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 8
         </a>
         ), pharmacology, and reproductive safety profiles. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Second-generation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1303232">
         <span class="h2">
          Refractory patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon clinical experience, prenatal manic and hypomanic episodes generally respond to sequential trials of
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         . (Response is defined as stabilizing the safety of the patient, as well as substantial improvement in the number, intensity, and frequency of symptoms.) However, for refractory patients who do not respond to antipsychotics, we suggest in order of preference
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and electroconvulsive therapy (ECT) [
         <a href="#rid64">
          64
         </a>
         ]. For patients unresponsive to sequential trials of lithium and ECT, other options include lithium plus an antipsychotic.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lithium
         </strong>
         – For pregnant patients with manic episodes that do not respond to multiple antipsychotics, we suggest
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , based upon its efficacy and side effects in randomized trials (which excluded pregnant patients) [
         <a href="#rid34">
          34
         </a>
         ]. Although lithium is generally regarded as teratogenic due to increased risks of cardiac defects (eg, Ebstein anomaly) [
         <a href="#rid60">
          60,61,65
         </a>
         ], many experts consider the absolute risk small [
         <a href="#rid1">
          1,29,38,56,65,66
         </a>
         ]. Clinicians can expect that up to approximately 50 percent of patients will respond, based upon trials in nonpregnant patients [
         <a href="#rid53">
          53
         </a>
         ]. Use of lithium in pregnant patients with bipolar disorder who do not respond to antipsychotics is consistent with practice guidelines [
         <a href="#rid46">
          46,67
         </a>
         ], including those from the United Kingdom National Institute for Health and Care Excellence [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose schedule for
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , use of serum concentrations to establish the proper dose, and lithium toxicity are discussed separately, as are using lithium during pregnancy and lithium’s reproductive safety profile. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Refractory patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electroconvulsive therapy
         </strong>
         – For pregnant patients with moderate to severe manic episodes that do not respond to sequential trials of antipsychotics and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , we suggest ECT, which is generally regarded as efficacious and safe [
         <a href="#rid68">
          68,69
         </a>
         ]. The use of ECT for pregnant bipolar patients is consistent with recommendations in multiple practice guidelines [
         <a href="#rid46">
          46,70,71
         </a>
         ], including those from the United Kingdom National Institute for Health and Care Excellence [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ECT is typically well tolerated and there are no absolute contraindications to ECT, even among patients whose general medical status is compromised [
         <a href="#rid68">
          68
         </a>
         ]. However, safety concerns regarding ECT necessitate preprocedure obstetric consultation (consistent with guideline recommendation), with emphasis upon assessing risk factors for spontaneous abortion, preterm labor, abruption, and uteroplacental insufficiency due to the association of ECT with transient increases or decreases in blood pressure and uterine contractions. The patient’s general medical status is also evaluated; medical consultation prior to ECT is discussed separately, as is the use of ECT for patients with general medical conditions. (See
         <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">
          "Medical evaluation for electroconvulsive therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults", section on 'Patients with comorbid general medical illness'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ECT is generally given three times per week on alternate days. Most patients regardless of indication remit with 6 to 12 treatments, but some patients require 20 or more. A review of prenatal ECT found that the mean number of treatments per ECT course was 11 [
         <a href="#rid69">
          69
         </a>
         ]. The number and frequency of treatments in the general use of ECT is discussed separately, as are the adjustments in ECT technique for pregnant patients. (See
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults", section on 'Treatment course'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">
          "Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Pregnancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following a course of ECT, clinicians usually prescribe maintenance pharmacotherapy. (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy", section on 'Choosing a specific maintenance treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence supporting the use of ECT includes studies that found ECT is effective for mania in patients who are not pregnant. (See
         <a class="medical medical_review" href="/z/d/html/14659.html" rel="external">
          "Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy", section on 'Mania'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, a review of observational studies of pregnant patients treated for mood or psychotic disorders with ECT found that among 68 cases with outcome data, at least partial remission occurred in 78 percent [
         <a href="#rid69">
          69
         </a>
         ]. Among the seven patients with bipolar disorder, remission occurred in five and partial remission in one. A subsequent retrospective study of 12 pregnant bipolar patients found that remission occurred in 11 (92 percent) [
         <a href="#rid72">
          72
         </a>
         ], and a case report described a pregnant patient with manic catatonia who remitted after two ECT treatments [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ECT during pregnancy is generally regarded as safe for the mother and fetus [
         <a href="#rid68">
          68,74,75
         </a>
         ]. Many authorities think that ECT poses fewer risks than untreated bipolar mood episodes and medications that are potentially teratogenic (eg,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and to a lesser extent
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ) [
         <a href="#rid1">
          1,68,69,76,77
         </a>
         ]. The reproductive safety profile of ECT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1703.html" rel="external">
          "Severe antenatal unipolar major depression: Choosing treatment", section on 'Electroconvulsive therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Electroconvulsive therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The general adverse effects of ECT include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment [
         <a href="#rid68">
          68
         </a>
         ]. These side effects and their management are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lithium
         </strong>
         <strong>
          plus an antipsychotic
         </strong>
         – For patients who do not respond to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         monotherapy and decline or do not have access to ECT, we suggest adding either a first- or second-generation antipsychotic to lithium, based upon randomized trials that excluded pregnant patients. (Response is defined as stabilizing the safety of the patient, as well as substantial improvement in the number, intensity, and frequency of symptoms.) For patients who do not respond to antipsychotics, lithium, and ECT, we concurrently start lithium plus an antipsychotic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No head-to-head trials have compared medication combinations consisting of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         plus an antipsychotic; we typically use lithium plus
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         . The choice of an antipsychotic is based upon factors including past response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost. As an example, if the patient previously showed a modest response to haloperidol and no response to risperidone, quetiapine, or olanzapine, we would choose lithium plus haloperidol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         plus an antipsychotic in randomized trials (that excluded pregnant patients) is discussed separately, as are the doses, side effects, pharmacology, and reproductive safety profiles. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Specific medication interactions that can occur may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Refractory patients who do not respond to or tolerate one
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         /antipsychotic combination should be treated with a second combination. We usually taper and discontinue the failed antipsychotic at the same time that a different antipsychotic is started and titrated up. The failed antipsychotic is generally tapered over one to two weeks by the same amount for each dose decrease (eg,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         8 mg per day is decreased by 2 mg per day, every one to three days).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1614170480">
         <span class="h2">
          Severe anxiety or insomnia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant patients with mania, hypomania, or mixed episodes who also suffer severe anxiety or insomnia despite ongoing pharmacotherapy, we suggest small doses of an adjunctive benzodiazepine on an as-needed basis for as short a time as possible [
         <a href="#rid1">
          1
         </a>
         ]. We prefer the high potency compounds
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         because they have shorter half-lives than
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         and
         <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">
          chlordiazepoxide
         </a>
         and are thus less likely to accumulate over time and cause toxicity [
         <a href="#rid1">
          1,78,79
         </a>
         ].
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          Alprazolam
         </a>
         is generally discouraged because its short half-life can produce rebound anxiety. We generally use lorazepam (eg, 0.5 or 1 mg) because it has no active metabolites and may cross the placenta at a lower rate than other benzodiazepines [
         <a href="#rid78">
          78
         </a>
         ]. Clonazepam (eg, 0.5 or 1 mg) is preferred for patients who require a drug with a longer half-life. The teratogenicity, pregnancy complications, and postnatal risks of benzodiazepines are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">
          "Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Benzodiazepines'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1830086042">
         <span class="h2">
          Drugs that are avoided
         </span>
         <span class="headingEndMark">
          —
         </span>
         For pregnant patients with manic episodes, we nearly always avoid
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         because of the risks of teratogenicity and adverse postnatal developmental outcomes [
         <a href="#rid5">
          5,80,81
         </a>
         ]. This approach is consistent with multiple practice guidelines [
         <a href="#rid46">
          46,49,67
         </a>
         ], including the American College of Obstetricians and Gynecologists [
         <a href="#rid29">
          29
         </a>
         ], the Canadian Network for Mood and Anxiety Treatments [
         <a href="#rid15">
          15
         </a>
         ], and the United Kingdom National Institute for Health and Care Excellence [
         <a href="#rid47">
          47
         </a>
         ]. One review concluded that valproate may be more teratogenic than any other neuropsychiatric drug [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         In addition, many regulatory agencies discourage or have banned the use of
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         in pregnant patients [
         <a href="#rid80">
          80,82
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The European Medicines Agency in 2018 recommended that
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         be banned for bipolar disorder during pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The United Kingdom in 2018 banned the use of
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         in women of childbearing potential unless they enroll in a pregnancy prevention program.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         France in 2017 banned the use of
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         in women with bipolar disorder who are either pregnant or of childbearing age and not using contraception.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The US Food and Drug Administration stated in 2016 that pregnant women with bipolar disorder should receive
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         only as a last resort.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The New Zealand Medicines and Medical Devices Safety Authority declared in 2014 that
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         is contraindicated in pregnancy.
        </p>
        <p>
        </p>
        <p>
         Evidence supporting the decision to not use
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         during pregnancy includes observational studies that were conducted largely in patients with epilepsy and yielded robust results [
         <a href="#rid46">
          46,80,82
         </a>
         ]. As an example, a meta-analysis of 14 studies (n&gt;100,000 pregnant women) found that the probability of major congenital malformations was three times greater in neonates exposed to valproate than unexposed neonates (odds ratio 3.4, 95% CI 2.5-4.5) [
         <a href="#rid47">
          47
         </a>
         ]. Although these were observational studies, the results are thought to be valid because of the large magnitude of the effect as well as other factors, including the variety of adverse effects, dose-dependent relationship between exposure and risks, and consistency of results across studies [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         Additional information about prenatal
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and the risks of major congenital malformations and adverse neurodevelopmental outcomes is discussed in the context of treating epilepsy. (See
         <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">
          "Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Risks with specific ASMs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3600428758">
         <span class="h1">
          MAINTENANCE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following recovery from prenatal bipolar mood episodes with pharmacotherapy, we suggest that patients receive maintenance treatment. For patients who decline maintenance pharmacotherapy, abrupt discontinuation of medications should be avoided. Rather, clinicians should attempt to taper and discontinue drugs over the course of at least 15 days to minimize the risk of relapse, based upon observational studies [
         <a href="#rid83">
          83
         </a>
         ]. Prenatal maintenance pharmacotherapy and the risk of abruptly discontinuing pharmacotherapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">
          "Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15701.html" rel="external">
          "Bipolar disorder in women: Contraception and preconception assessment and counseling", section on 'Relapse after discontinuing pharmacotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3909095922">
         <span class="h1">
          SUBSYNDROMAL SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant patients with subthreshold symptoms of hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ) or mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ) are at risk for suffering full-blown episodes [
         <a href="#rid24">
          24
         </a>
         ]. Management of subsyndromal symptoms is based primarily upon clinical experience and patient preference. One strategy is watchful waiting (eg, monitoring patients once a week) and optimizing sleep  (
         <a class="graphic graphic_table graphicRef71116" href="/z/d/graphic/71116.html" rel="external">
          table 9
         </a>
         ). Another strategy is prescribing a low dose of a benzodiazepine (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         0.5 mg once or twice daily) or a low dose of an antipsychotic (eg,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         0.5 mg once daily or
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         25 mg once or twice daily), and titrating according to efficacy and adverse effects.
        </p>
        <p class="headingAnchor" id="H1828161573">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">
          "Society guideline links: Bipolar disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13500325">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (See
         <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">
          "Patient education: Bipolar disorder (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (See
         <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">
          "Patient education: Bipolar disorder (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These educational materials can be used as part of psychoeducational psychotherapy. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'
         </a>
         .)
        </p>
        <p>
         The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=14647" target="_blank">
          website
         </a>
         or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.
        </p>
        <p>
         More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).
        </p>
        <p>
         The Depression and Bipolar Support Alliance (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=14647" target="_blank">
          the website
         </a>
         or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.
        </p>
        <p>
         The National Alliance on Mental Illness (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=14647" target="_blank">
          the website
         </a>
         or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.
        </p>
        <p class="headingAnchor" id="H116932847">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ). Pregnant patients can be screened for bipolar disorder with the Edinburgh Postnatal Depression Scale  (
         <a class="graphic graphic_figure graphicRef67741" href="/z/d/graphic/67741.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef81407" href="/z/d/graphic/81407.html" rel="external">
          figure 2
         </a>
         ) and the Mood Disorder Questionnaire  (
         <a class="graphic graphic_table graphicRef53409" href="/z/d/graphic/53409.html" rel="external">
          table 5
         </a>
         ). An overview of screening for and diagnosing bipolar disorder in pregnant women is presented in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef122826" href="/z/d/graphic/122826.html" rel="external">
          algorithm 1
         </a>
         ). Patients who screen positive require a diagnostic interview to establish the diagnosis. (See
         <a class="local">
          'Definition of bipolar disorder'
         </a>
         above and
         <a class="local">
          'Screening and diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharmacotherapy is indicated for pregnant patients with manic or hypomanic episodes that are characterized by:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Suicidal or homicidal ideation or behavior
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aggressive behavior
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Psychotic features (delusions or hallucinations)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Poor judgement that places the patient or others at imminent risk of being harmed
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate to severe impairment of social or occupational functioning
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Involvement in pleasurable activities that have a high potential for painful consequences (eg, unrestrained buying sprees or sexual indiscretions)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         (See
         <a class="local">
          'Indications for pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinicians treating pregnant patients with manic or hypomanic episodes should attempt to use drugs with fewer known teratogenic and postnatal effects, monotherapy, and the minimal effective dose. An individual drug trial typically lasts three weeks before determining the medication is beneficial. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For manic and hypomanic pregnant patients, we suggest first-generation antipsychotics rather than other medications (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          Haloperidol
         </a>
         has been widely used, but reasonable alternatives include
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         . (See
         <a class="local">
          'First-line medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pregnant patients with manic or hypomanic episodes who do not respond to or tolerate first-generation antipsychotics, we suggest
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         rather than other drugs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, reasonable alternatives in order of preference are
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         . (See
         <a class="local">
          'Resistant patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant patients with refractory manic or hypomanic episodes that do not respond to antipsychotics are often treated with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , electroconvulsive therapy, or lithium plus an antipsychotic. (See
         <a class="local">
          'Refractory patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small doses of an adjunctive benzodiazepine (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) on an as-needed basis can be helpful for severe anxiety or insomnia. (See
         <a class="local">
          'Severe anxiety or insomnia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subsyndromal symptoms of hypomania or mania can be managed with watchful waiting and optimizing sleep, or with a benzodiazepine or antipsychotic at a low dose. (See
         <a class="local">
          'Subsyndromal symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayad M, Costantine MM. Epidemiology of medications use in pregnancy. Semin Perinatol 2015; 39:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ 2016; 532:h5918.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark CT, Wisner KL. Treatment of Peripartum Bipolar Disorder. Obstet Gynecol Clin North Am 2018; 45:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kendig S, Keats JP, Hoffman MC, et al. Consensus Bundle on Maternal Mental Health: Perinatal Depression and Anxiety. Obstet Gynecol 2017; 129:422.
          </a>
         </li>
         <li class="breakAll">
          Moses-Kolko EL, Clark CT, DeBrunner S, Wisner KL. Reproductive-age women with bipolar II disorder. In: Bipolar II Disorder: Recognition, Understanding, and Treatment, Swartz HA, Suppes T (Eds), American Psychiatric Association Publishing, Washington, DC 2019. p.263.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987; 150:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor E, Rossom RC, Henninger M, et al. Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016; 315:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Obstetric Practice. The American College of Obstetricians and Gynecologists Committee Opinion no. 630. Screening for perinatal depression. Obstet Gynecol 2015; 125:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong Q, Gelaye B, Rondon M, et al. Comparative performance of Patient Health Questionnaire-9 and Edinburgh Postnatal Depression Scale for screening antepartum depression. J Affect Disord 2014; 162:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barthel D, Barkmann C, Ehrhardt S, et al. Screening for depression in pregnant women from Côte d׳Ivoire and Ghana: Psychometric properties of the Patient Health Questionnaire-9. J Affect Disord 2015; 187:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidebottom AC, Harrison PA, Godecker A, Kim H. Validation of the Patient Health Questionnaire (PHQ)-9 for prenatal depression screening. Arch Womens Ment Health 2012; 15:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siu AL, US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, et al. Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 315:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.
          </a>
         </li>
         <li class="breakAll">
          Position Statement on Screening and Treatment of Mood and Anxiety Disorders During Pregnancy and Postpartum. https://www.psychiatry.org/home/policy-finder?k=Screening and Treatment of Mood and Anxiety Disorders During Pregnancy and Postpartum (Accessed on September 15, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chessick CA, Dimidjian S. Screening for bipolar disorder during pregnancy and the postpartum period. Arch Womens Ment Health 2010; 13:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157:1873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu C, Xiang YT, Wang G, et al. Screening for bipolar disorder with the Mood Disorders Questionnaire in patients diagnosed as major depressive disorder - the experience in China. J Affect Disord 2012; 141:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerimele JM, Chwastiak LA, Chan YF, et al. The presentation, recognition and management of bipolar depression in primary care. J Gen Intern Med 2013; 28:1648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler RC, Akiskal HS, Angst J, et al. Validity of the assessment of bipolar spectrum disorders in the WHO CIDI 3.0. J Affect Disord 2006; 96:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhat A, Cerimele JM, Byatt N. Pregnant and Postpartum Women With Bipolar Disorder: Taking the Care to Where They Are. Psychiatr Serv 2018; 69:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrill L, Mittal L, Nicoloro J, et al. Screening for bipolar disorder during pregnancy. Arch Womens Ment Health 2015; 18:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma V, Bergink V, Berk M, et al. Childbirth and prevention of bipolar disorder: an opportunity for change. Lancet Psychiatry 2019; 6:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark CT, Sit DK, Driscoll K, et al. DOES SCREENING WITH THE MDQ AND EPDS IMPROVE IDENTIFICATION OF BIPOLAR DISORDER IN AN OBSTETRICAL SAMPLE? Depress Anxiety 2015; 32:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frey BN, Simpson W, Wright L, Steiner M. Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period. J Clin Psychiatry 2012; 73:1456.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed Obstet Gynecol 2018; 131:185. Reaffirmed 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005; 186:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah N. Mood disorder in the perinatal period. BMJ 2012; 344:e1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378:1306.
          </a>
         </li>
         <li class="breakAll">
          Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disorder in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex 2010. p.463.
         </li>
         <li class="breakAll">
          Ray-Griffith SL, Newport DJ, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington 2017. p.1543.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergink V, Bouvy PF, Vervoort JS, et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 2012; 169:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santucci AK, Singer LT, Wisniewski SR, et al. One-Year Developmental Outcomes for Infants of Mothers With Bipolar Disorder. J Clin Psychiatry 2017; 78:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Treatment of Patients with Bipolar Disorder, Second Edition, 2002. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf (Accessed on January 16, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol 2017; 31:519.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence (NICE). Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance. Published December 2014, updated April 2018, https://www.nice.org.uk/guidance/cg192 (Accessed on September 15, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005; 66:317.
          </a>
         </li>
         <li class="breakAll">
          Janicak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacotherapy, Fifth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.367.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.
          </a>
         </li>
         <li class="breakAll">
          Briggs GG, Freeman RK, Towers CV, Forinash AB. Diphenhydramine. In: Drugs in Pregnancy and Lactation, Eleventh Edition, Wolters Kluwer, Philadelphia 2017. p.434.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.
          </a>
         </li>
         <li class="breakAll">
          Burt VK, Rasminsky S, Murphy-Barzilay E, Suri R. Women. In: The American Psychiatric Association Publishing Textbook of Psychiatry, Seventh Edition, Roberts LW (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.1113.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010; 12:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012; 46:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002; 47:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fornaro M, Maritan E, Ferranti R, et al. Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. Am J Psychiatry 2020; 177:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl 2015; :1.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Use of electroconvulsive therapy in special populations. In: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition, American Psychiatric Association, Washington, DC 2001. p.31.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009; 71:235.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Treatment of Patients With Bipolar Disorder Second Edition http://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulbul F, Copoglu US, Alpak G, et al. Electroconvulsive therapy in pregnant patients. Gen Hosp Psychiatry 2013; 35:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinna M, Manchia M, Pillai G, et al. Efficacy and safety of electroconvulsive therapy in the first trimester of pregnancy: a case of severe manic catatonia. Bipolar Disord 2015; 17:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition http://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46:710.
          </a>
         </li>
         <li class="breakAll">
          Burt VK, Suri R, Edelstein C. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Sixth Edition, Hales RE, Yudofsky SC, Roberts LW (Eds), American Psychiatric Publishing, Washington, DC 2014. p.1319.
         </li>
         <li class="breakAll">
          Zappert LN, Rasgon NL. Management of bipolar disorders in women. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA (Ed), American Psychiatric Publishing, Inc., Washington, DC 2010. p.425.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ 2018; 361:k1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wieck A, Jones S. Dangers of valproate in pregnancy. BMJ 2018; 361:k1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade C. Valproate in Pregnancy: Recent Research and Regulatory Responses. J Clin Psychiatry 2018; 79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164:1817.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14647 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Management of bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26358804" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Epidemiology of medications use in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26791406" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Management of psychotropic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26791406" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Management of psychotropic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30092918" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of Peripartum Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28178041" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Consensus Bundle on Maternal Mental Health: Perinatal Depression and Anxiety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28178041" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Consensus Bundle on Maternal Mental Health: Perinatal Depression and Anxiety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3651732" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26813212" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25932866" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The American College of Obstetricians and Gynecologists Committee Opinion no. 630. Screening for perinatal depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24766996" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Comparative performance of Patient Health Questionnaire-9 and Edinburgh Postnatal Depression Scale for screening antepartum depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26343851" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Screening for depression in pregnant women from Côte d׳Ivoire and Ghana: Psychometric properties of the Patient Health Questionnaire-9.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22983357" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Validation of the Patient Health Questionnaire (PHQ)-9 for prenatal depression screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26813211" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20198393" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Screening for bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11058490" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22436092" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Screening for bipolar disorder with the Mood Disorders Questionnaire in patients diagnosed as major depressive disorder - the experience in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23835789" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The presentation, recognition and management of bipolar depression in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16997383" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Validity of the assessment of bipolar spectrum disorders in the WHO CIDI 3.0.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30122137" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pregnant and Postpartum Women With Bipolar Disorder: Taking the Care to Where They Are.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25968603" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Screening for bipolar disorder during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30981755" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Childbirth and prevention of bipolar disorder: an opportunity for change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26059839" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : DOES SCREENING WITH THE MDQ AND EPDS IMPROVE IDENTIFICATION OF BIPOLAR DISORDER IN AN OBSTETRICAL SAMPLE?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23146292" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23146292" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422871" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329543" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15928351" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Bipolar disorder and childbirth: the importance of recognising risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20693466" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22381523" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mood disorder in the perinatal period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21851976" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21851976" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21851976" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22407083" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prevention of postpartum psychosis and mania in women at high risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Treatment of mood disorders during pregnancy and postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17671284" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15816786" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28068465" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : One-Year Developmental Outcomes for Infants of Mothers With Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11958165" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Practice guideline for the treatment of patients with bipolar disorder (revision).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11958165" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Practice guideline for the treatment of patients with bipolar disorder (revision).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19347775" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19419382" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28440103" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28440103" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18480684" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Maternal use of antipsychotics in early pregnancy and delivery outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766297" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15766297" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18787227" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antipsychotic therapy during early and late pregnancy. A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17845269" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17845269" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8615404" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8615404" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461391" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Use and safety of antipsychotic drugs during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17343431" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Psychotropic drugs in pregnancy and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425293" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20113298" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22009159" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22316639" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12085677" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Managing bipolar disorder during pregnancy: weighing the risks and benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31623458" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21088587" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Drug treatment for mood disorders in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26344706" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Use of psychotropic drugs during pregnancy and breast-feeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26344706" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Use of psychotropic drugs during pregnancy and breast-feeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19073751" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : ECT in pregnancy: a review of the literature from 1941 to 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19073751" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : ECT in pregnancy: a review of the literature from 1941 to 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23890597" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Electroconvulsive therapy in pregnant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25854818" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Efficacy and safety of electroconvulsive therapy in the first trimester of pregnancy: a case of severe manic catatonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Practice guideline for the treatment of patients with major depressive disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Practice guideline for the treatment of patients with major depressive disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8045538" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Use of electroconvulsive therapy during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11692973" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The use of electroconvulsive therapy in special patient populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11692973" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The use of electroconvulsive therapy in special patient populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11692973" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The use of electroconvulsive therapy in special patient populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29669717" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Weighing the risks of valproate in women who could become pregnant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29669728" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Dangers of valproate in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29873961" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Valproate in Pregnancy: Recent Research and Regulatory Responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18056236" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
